bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplementary Table S5 from Trends and Disparities in Curative-Intent Treatment for Early-Stage Non–Small Cell Lung Cancer: A Population-Based Analysis of Surgery and SBRT
Authors: Liu Qinran , Medina Heidy N. , Rodriguez Estelamari , Jacobs Kamaria T. , Brown Clyde , Koru-Sengul Tulay , Lopes Gilberto , Pinheiro Paulo S.
Published: April 2024

Supplementary Table S5 shows the stratification analyses of receipt of curative-intent surgery and receipt of any curative-intent treatment by region in Florida from 2005 to 2017.
Supplementary Table S4 from Trends and Disparities in Curative-Intent Treatment for Early-Stage Non–Small Cell Lung Cancer: A Population-Based Analysis of Surgery and SBRT
Authors: Liu Qinran , Medina Heidy N. , Rodriguez Estelamari , Jacobs Kamaria T. , Brown Clyde , Koru-Sengul Tulay , Lopes Gilberto , Pinheiro Paulo S.
Published: April 2024

Supplementary Table S4 shows the full list of determinants of receipt of curative surgery and any curative-intent treatment in Florida from 2005 to 2017.
Supplementary Figure 1 from The Associations between Intakes of One-Carbon Metabolism–Related Vitamins and Breast Density among Young Women
Authors: Han Eunyoung , Van Horn Linda , Snetselaar Linda , Shepherd John A. , Park Yoon Jung , Kim Hyesook , Jung Seungyoun , Dorgan Joanne F.
Published: April 2024

Supplementary Figure 1 shows a flow diagram of study population
Supplementary Table S2 from Do Contemporary Cancer Survivors Experience Better Quality of Life? Evaluating a Decade of SEER Medicare Health Outcomes Survey Data
Authors: Allaire Benjamin T. , Horvath Marc L. , Lines Lisa M. , Davidoff Amy J. , Smith Ashley Wilder , Jensen Roxanne E.
Published: April 2024

Supplementary Table S2 displays the complete pre-matching covariate balance statistics
Supplementary Table S3 from Prevalence and Correlates of Post-Diagnosis Alcohol Use among Cancer Survivors
Authors: Heffner Jaimee L. , Ton Mimi , Jones Salene M.W. , Malen Rachel C. , Cohen Stacey A. , Newcomb Polly A.
Published: April 2024

Supplementary Table S3 provides the unadjusted odds ratios and 95% confidence intervals from separate, unweighted, sex- stratified models of post-diagnosis alcohol use in relation to cancer site
Supplementary Table S2 from Prevalence and Correlates of Post-Diagnosis Alcohol Use among Cancer Survivors
Authors: Heffner Jaimee L. , Ton Mimi , Jones Salene M.W. , Malen Rachel C. , Cohen Stacey A. , Newcomb Polly A.
Published: April 2024

Supplementary Table S2 provides the unadjusted odds ratios and 95% confidence intervals from unweighted models evaluating each personal, clinical, and social characteristic separately in relation to post-diagnosis alcohol use (n=1,488)
Supplemental Table 1 from Epidemiologic Factors in Relation to Colorectal Cancer Risk and Survival by Genotoxic Colibactin Mutational Signature
Authors: Thomas Claire E. , Georgeson Peter , Qu Conghui , Steinfelder Robert S. , Buchanan Daniel D. , Song Mingyang , Harrison Tabitha A. , Um Caroline Y. , Hullar Meredith A. , Jenkins Mark A. , Van Guelpen Bethany , Lynch Brigid M. , Melaku Yohannes Adama , Huyghe Jeroen R. , Aglago Elom K. , Berndt Sonja I. , Boardman Lisa A. , Campbell Peter T. , Cao Yin , Chan Andrew T. , Drew David A. , Figueiredo Jane C. , French Amy J. , Giannakis Marios , Goode Ellen L. , Gruber Stephen B. , Gsur Andrea , Gunter Marc J. , Hoffmeister Michael , Hsu Li , Huang Wen-Yi , Moreno Victor , Murphy Neil , Newcomb Polly A. , Newton Christina C. , Nowak Jonathan A. , Obón-Santacana Mireia , Ogino Shuji , Sun Wei , Toland Amanda E. , Trinh Quang M. , Ugai Tomotaka , Zaidi Syed H. , Peters Ulrike , Phipps Amanda I.
Published: April 2024

Supplemental Table 1 shows the odds ratios and 95% confidence intervals for the association of epidemiologic factors with CRC risk by SBS88 signature and APC:c.835-8A>G somatic mutation status.
Supplementary Table 3 from Risk Factors for Ovarian Cancer by BRCA Status: A Collaborative Case-Only Analysis
Authors: Gersekowski Kate , Na Renhua , Alsop Kathryn , Delahunty Rachel , Goode Ellen L. , Cunningham Julie M. , Winham Stacey J. , Pharoah Paul D.P. , Song Honglin , Webb Penelope M.
Published: April 2024

Supplementary Table 3: Case-only comparisons between BRCA variant carriers and non-carriers, high grade serous cancer and endometrioid/clear cell carcinomas
Supplementary Table 6. from Associations between Plasma Tocopherols and Lung Cancer Risk: Results from the Southern Community Cohort Study
Authors: Yoon Hyung-Suk , Wu Jie , Shidal Chris , Sun Yan , Franke Adrian A. , Yang Jae Jeong , Braithwaite Dejana , Courtney Regina , Cai Hui , Blot William J. , Shu Xiao-Ou , Zheng Wei , Cai Qiuyin
Published: April 2024

Association between Plasma Tocopherols and Histological Subtype of Lung Cancer
Supplementary Table 2 from Risk Factors for Ovarian Cancer by BRCA Status: A Collaborative Case-Only Analysis
Authors: Gersekowski Kate , Na Renhua , Alsop Kathryn , Delahunty Rachel , Goode Ellen L. , Cunningham Julie M. , Winham Stacey J. , Pharoah Paul D.P. , Song Honglin , Webb Penelope M.
Published: April 2024

Supplementary Table 2: Case-only comparisons between BRCA variant carriers and non-carriers, all invasive cancers
Supplementary Table 5. from Associations between Plasma Tocopherols and Lung Cancer Risk: Results from the Southern Community Cohort Study
Authors: Yoon Hyung-Suk , Wu Jie , Shidal Chris , Sun Yan , Franke Adrian A. , Yang Jae Jeong , Braithwaite Dejana , Courtney Regina , Cai Hui , Blot William J. , Shu Xiao-Ou , Zheng Wei , Cai Qiuyin
Published: April 2024

Association between Plasma Tocopherols and Lung Cancer Risk by Use of Dietary Supplements
Supplementary Table 1 from Risk Factors for Ovarian Cancer by BRCA Status: A Collaborative Case-Only Analysis
Authors: Gersekowski Kate , Na Renhua , Alsop Kathryn , Delahunty Rachel , Goode Ellen L. , Cunningham Julie M. , Winham Stacey J. , Pharoah Paul D.P. , Song Honglin , Webb Penelope M.
Published: April 2024

Supplementary Table 1: Characteristics of the contributing studies
Supplementary Table S1 from Sleep and Risk of Pancreatic Cancer in the UK Biobank
Authors: Freeman Joshua R. , Saint-Maurice Pedro F. , Zhang Ting , Matthews Charles E. , Stolzenberg-Solomon Rachael Z.
Published: April 2024

Supplementary Table S1. P-values for interactions between smoking status, sex, and age, and the sleep characteristic and PDAC associations.
Supplemental Table S8 from Risk of Gastric Adenocarcinoma in a Multiethnic Population Undergoing Routine Care: An Electronic Health Records Cohort Study
Authors: Huang Robert J. , Huang Edward S. , Mudiganti Satish , Chen Tony , Martinez Meghan C. , Ramrakhiani Sanjay , Han Summer S. , Hwang Joo Ha , Palaniappan Latha P. , Liang Su-Ying
Published: April 2024

Supplemental Table S8: Univariable and multivariable predictors of gastric adenocarcinoma (GAC), excluding cardia GACs and C16.8, C16.9. Hazard ratios (HRs) with 95% confidence intervals (Cis) are presented in both univariable and multivariable analysis. EHR, electronic health record; H2 blocker, histamine type 2 receptor blocker; Hp, Helicobacter pylori; ICD, international classification of disease; LOINC, Logical Observation Identifiers, Names and Codes; NSAID, non-steroidal anti-inflammatory drug; PPI, proton pump inhibitor.
Supplemental Table S6 from Risk of Gastric Adenocarcinoma in a Multiethnic Population Undergoing Routine Care: An Electronic Health Records Cohort Study
Authors: Huang Robert J. , Huang Edward S. , Mudiganti Satish , Chen Tony , Martinez Meghan C. , Ramrakhiani Sanjay , Han Summer S. , Hwang Joo Ha , Palaniappan Latha P. , Liang Su-Ying
Published: April 2024

Supplemental Table S6: Persons at risk for gastric adenocarcinoma (GAC), including cardia GAC, at time point of observation. Hp, Helicobacter pylori.
Supplemental Figure 2 from Interaction between Continuous Pack-Years Smoked and Polygenic Risk Score on Lung Cancer Risk: Prospective Results from the Framingham Heart Study
Authors: Duncan Meredith S. , Diaz-Zabala Hector , Jaworski James , Tindle Hilary A. , Greevy Robert A. , Lipworth Loren , Hung Rayjean J. , Freiberg Matthew S. , Aldrich Melinda C.
Published: April 2024

Supplemental Figure 2: Overlaid histograms of pack-years smoked by smoking status. This plot shows that currently smoking individuals tended to incur more pack-years smoked than formerly smoking individuals.
Supplemental Table S4 from Risk of Gastric Adenocarcinoma in a Multiethnic Population Undergoing Routine Care: An Electronic Health Records Cohort Study
Authors: Huang Robert J. , Huang Edward S. , Mudiganti Satish , Chen Tony , Martinez Meghan C. , Ramrakhiani Sanjay , Han Summer S. , Hwang Joo Ha , Palaniappan Latha P. , Liang Su-Ying
Published: April 2024

Supplemental Table S4: Recoding schema for family history of gastric adenocarcinoma using information from family history structured data element.
Supplemental Table S2 from Risk of Gastric Adenocarcinoma in a Multiethnic Population Undergoing Routine Care: An Electronic Health Records Cohort Study
Authors: Huang Robert J. , Huang Edward S. , Mudiganti Satish , Chen Tony , Martinez Meghan C. , Ramrakhiani Sanjay , Han Summer S. , Hwang Joo Ha , Palaniappan Latha P. , Liang Su-Ying
Published: April 2024

Supplemental Table S2: rules-based consensus to phenotype dispensation of medical therapy to eradicate Helicobacter pylori (Hp). Count depicts the number of prescriptions identified within cohort.
Supplementary Table 8 from The Impact of Inherited Genetic Variation on DNA Methylation in Prostate Cancer and Benign Tissues of African American and European American Men
Authors: Delgado Dayana , Gillard Marc , Tong Lin , Demanelis Kathryn , Oliva Meritxell , Gleason Kevin J. , Chernoff Meytal , Chen Lin , Paner Gladell P. , Vander Griend Donald , Pierce Brandon L.
Published: April 2024

Supplementary Table 8 shows the cis-meQTLs residing in same location as PCa-risk SNPs with p < 5x10-8 in the Schumacher et a. GWAS of PCa in EA benign tissue
Supplemental Table 2 from Oncogenic Oral Human Papillomavirus Clearance Patterns over 10 Years
Authors: D'Souza Gypsyamber , Tewari Sakshi R. , Troy Tanya , Webster-Cyriaque Jennifer , Wiley Dorothy J. , Lahiri Cecile Delille , Palella Frank Joseph , Gillison Maura L. , Strickler Howard D. , Struijk Linda , Waterboer Tim , Ho Ken , Kwait Jennafer , Lazar Jason , Weber Kathleen M. , Fakhry Carole
Published: April 2024

Supplemental Table 2: Multivariate predictors of clearance, across the four different clearance definitions evaluated in this study.
Supplemental Table 1 from Oncogenic Oral Human Papillomavirus Clearance Patterns over 10 Years
Authors: D'Souza Gypsyamber , Tewari Sakshi R. , Troy Tanya , Webster-Cyriaque Jennifer , Wiley Dorothy J. , Lahiri Cecile Delille , Palella Frank Joseph , Gillison Maura L. , Strickler Howard D. , Struijk Linda , Waterboer Tim , Ho Ken , Kwait Jennafer , Lazar Jason , Weber Kathleen M. , Fakhry Carole
Published: April 2024

Supplemental Table 1: Proportion of 1833 subjects screened who have oncogenic oral HPV DNA and cancer characteristics.
Supplementary Table 3 from The Impact of Inherited Genetic Variation on DNA Methylation in Prostate Cancer and Benign Tissues of African American and European American Men
Authors: Delgado Dayana , Gillard Marc , Tong Lin , Demanelis Kathryn , Oliva Meritxell , Gleason Kevin J. , Chernoff Meytal , Chen Lin , Paner Gladell P. , Vander Griend Donald , Pierce Brandon L.
Published: April 2024

Supplementary Table 3 shows the tissue specificity of cis-meQTLs in AA and EA men
Supplemental Figure 6 from Oncogenic Oral Human Papillomavirus Clearance Patterns over 10 Years
Authors: D'Souza Gypsyamber , Tewari Sakshi R. , Troy Tanya , Webster-Cyriaque Jennifer , Wiley Dorothy J. , Lahiri Cecile Delille , Palella Frank Joseph , Gillison Maura L. , Strickler Howard D. , Struijk Linda , Waterboer Tim , Ho Ken , Kwait Jennafer , Lazar Jason , Weber Kathleen M. , Fakhry Carole
Published: April 2024

Supplemental Figure 6: Effect of HIV and CD4 on prevalent (SF6a) incident (SF6b) infections.
Supplementary Table 2 from The Impact of Inherited Genetic Variation on DNA Methylation in Prostate Cancer and Benign Tissues of African American and European American Men
Authors: Delgado Dayana , Gillard Marc , Tong Lin , Demanelis Kathryn , Oliva Meritxell , Gleason Kevin J. , Chernoff Meytal , Chen Lin , Paner Gladell P. , Vander Griend Donald , Pierce Brandon L.
Published: April 2024

Supplementary Table 2 shows the characteristics of prostatectomy patients recruited at the University of Chicago Medical Center
Supplemental Figure 5 from Oncogenic Oral Human Papillomavirus Clearance Patterns over 10 Years
Authors: D'Souza Gypsyamber , Tewari Sakshi R. , Troy Tanya , Webster-Cyriaque Jennifer , Wiley Dorothy J. , Lahiri Cecile Delille , Palella Frank Joseph , Gillison Maura L. , Strickler Howard D. , Struijk Linda , Waterboer Tim , Ho Ken , Kwait Jennafer , Lazar Jason , Weber Kathleen M. , Fakhry Carole
Published: April 2024

Supplemental Figure 5: Effect of HPV16 qPCR copynumber(CN) per cell on HPV16 infections.
Supplementary Table 19 from The Impact of Inherited Genetic Variation on DNA Methylation in Prostate Cancer and Benign Tissues of African American and European American Men
Authors: Delgado Dayana , Gillard Marc , Tong Lin , Demanelis Kathryn , Oliva Meritxell , Gleason Kevin J. , Chernoff Meytal , Chen Lin , Paner Gladell P. , Vander Griend Donald , Pierce Brandon L.
Published: April 2024

Supplementary Table 19 shows the benign tissue p-values of meQTLs (FDR < 0.05) discovered in tumor tissue
Supplementary Table 18 from The Impact of Inherited Genetic Variation on DNA Methylation in Prostate Cancer and Benign Tissues of African American and European American Men
Authors: Delgado Dayana , Gillard Marc , Tong Lin , Demanelis Kathryn , Oliva Meritxell , Gleason Kevin J. , Chernoff Meytal , Chen Lin , Paner Gladell P. , Vander Griend Donald , Pierce Brandon L.
Published: April 2024

Supplementary Table 18 shows the co-localized PCa-risk SNPs meQTL and eQTL status in whole blood based on the QTLbase database
Supplemental Figure 3 from Oncogenic Oral Human Papillomavirus Clearance Patterns over 10 Years
Authors: D'Souza Gypsyamber , Tewari Sakshi R. , Troy Tanya , Webster-Cyriaque Jennifer , Wiley Dorothy J. , Lahiri Cecile Delille , Palella Frank Joseph , Gillison Maura L. , Strickler Howard D. , Struijk Linda , Waterboer Tim , Ho Ken , Kwait Jennafer , Lazar Jason , Weber Kathleen M. , Fakhry Carole
Published: April 2024

Supplemental Figure 3: Effect of age on prevalent (SF3a) incident (SF3b) infections.
Supplementary Table 14 from The Impact of Inherited Genetic Variation on DNA Methylation in Prostate Cancer and Benign Tissues of African American and European American Men
Authors: Delgado Dayana , Gillard Marc , Tong Lin , Demanelis Kathryn , Oliva Meritxell , Gleason Kevin J. , Chernoff Meytal , Chen Lin , Paner Gladell P. , Vander Griend Donald , Pierce Brandon L.
Published: April 2024

Supplementary Table 14 shows the characteristics of PCa-risk SNPs and 16 CpGs tested for co-localization in tumor tissue
Supplementary Table 12 from The Impact of Inherited Genetic Variation on DNA Methylation in Prostate Cancer and Benign Tissues of African American and European American Men
Authors: Delgado Dayana , Gillard Marc , Tong Lin , Demanelis Kathryn , Oliva Meritxell , Gleason Kevin J. , Chernoff Meytal , Chen Lin , Paner Gladell P. , Vander Griend Donald , Pierce Brandon L.
Published: April 2024

Supplementary Table 12 shows the cis-meQTLs residing in same location as PCa-risk SNPs with p < 5x10-8 in the Schumacher et al. GWAS of PCa in AA tumor tissue
Supplementary Table 1 from Racial and Ethnic Disparities in Hepatocellular Carcinoma Treatment Receipt in the United States: A Systematic Review and Meta-Analysis
Authors: Wagle Nikita Sandeep , Park Sulki , Washburn David , Ohsfeldt Robert , Kum Hye-Chung , Singal Amit G.
Published: April 2024

MOOSE Checklist
Supplementary Table 11 from The Impact of Inherited Genetic Variation on DNA Methylation in Prostate Cancer and Benign Tissues of African American and European American Men
Authors: Delgado Dayana , Gillard Marc , Tong Lin , Demanelis Kathryn , Oliva Meritxell , Gleason Kevin J. , Chernoff Meytal , Chen Lin , Paner Gladell P. , Vander Griend Donald , Pierce Brandon L.
Published: April 2024

Supplementary Table 11 shows the posterior probabilities that GWAS and meQTL signals are caused by independent SNPs (PP3) in benign tissue
Supplementary Figure 5 from Racial and Ethnic Disparities in Hepatocellular Carcinoma Treatment Receipt in the United States: A Systematic Review and Meta-Analysis
Authors: Wagle Nikita Sandeep , Park Sulki , Washburn David , Ohsfeldt Robert , Kum Hye-Chung , Singal Amit G.
Published: April 2024

Supplementary figure 5 shows that there were no significant differences in any (A) or curative treatment (B) receipt between Asian and White patients.
Supplementary Table 10 from The Impact of Inherited Genetic Variation on DNA Methylation in Prostate Cancer and Benign Tissues of African American and European American Men
Authors: Delgado Dayana , Gillard Marc , Tong Lin , Demanelis Kathryn , Oliva Meritxell , Gleason Kevin J. , Chernoff Meytal , Chen Lin , Paner Gladell P. , Vander Griend Donald , Pierce Brandon L.
Published: April 2024

Supplementary Table 10 shows the posterior probabilities that GWAS and meQTL traits share the same causal variant in benign tissue
Supplementary Figure 3 from Racial and Ethnic Disparities in Hepatocellular Carcinoma Treatment Receipt in the United States: A Systematic Review and Meta-Analysis
Authors: Wagle Nikita Sandeep , Park Sulki , Washburn David , Ohsfeldt Robert , Kum Hye-Chung , Singal Amit G.
Published: April 2024

Supplementary figure 3 shows that the pooled proportion for curative HCC treatment among early-stage HCC patients is 51.4%.
Supplementary Figure 9 from The Impact of Inherited Genetic Variation on DNA Methylation in Prostate Cancer and Benign Tissues of African American and European American Men
Authors: Delgado Dayana , Gillard Marc , Tong Lin , Demanelis Kathryn , Oliva Meritxell , Gleason Kevin J. , Chernoff Meytal , Chen Lin , Paner Gladell P. , Vander Griend Donald , Pierce Brandon L.
Published: April 2024

Supplementary Figure 9 shows that In benign tissue, there is no detectable meQTL for cg01859299 in the IRX4 region.
Supplementary Figure 8 from The Impact of Inherited Genetic Variation on DNA Methylation in Prostate Cancer and Benign Tissues of African American and European American Men
Authors: Delgado Dayana , Gillard Marc , Tong Lin , Demanelis Kathryn , Oliva Meritxell , Gleason Kevin J. , Chernoff Meytal , Chen Lin , Paner Gladell P. , Vander Griend Donald , Pierce Brandon L.
Published: April 2024

Supplementary Figure 8 shows the regional association plots for the AA meQTL and PCa GWAS signal in the MLPH region
Supplementary Figure 6 from The Impact of Inherited Genetic Variation on DNA Methylation in Prostate Cancer and Benign Tissues of African American and European American Men
Authors: Delgado Dayana , Gillard Marc , Tong Lin , Demanelis Kathryn , Oliva Meritxell , Gleason Kevin J. , Chernoff Meytal , Chen Lin , Paner Gladell P. , Vander Griend Donald , Pierce Brandon L.
Published: April 2024

Supplementary Figure 6 shows the co-localization of PCa GWAS signal with a tumor meQTL in IRX4 region (EA patients).
Supplementary Table 6 from Association of Fibroids, Endometriosis, and Gynecologic Surgeries with Breast Cancer Incidence and Hormone Receptor Subtypes
Authors: Zeldin Jordan , Sandler Dale P. , Ogunsina Kemi , O'Brien Katie M.
Published: April 2024

Association between fibroids and triple negative subtype among cases, stratified by race/ethnicity using logistic regression models
Supplementary Figure 3 from The Impact of Inherited Genetic Variation on DNA Methylation in Prostate Cancer and Benign Tissues of African American and European American Men
Authors: Delgado Dayana , Gillard Marc , Tong Lin , Demanelis Kathryn , Oliva Meritxell , Gleason Kevin J. , Chernoff Meytal , Chen Lin , Paner Gladell P. , Vander Griend Donald , Pierce Brandon L.
Published: April 2024

Supplementary Figure 3 shows the CpG context of the mCpGs identified
Supplementary Table 5 from Association of Fibroids, Endometriosis, and Gynecologic Surgeries with Breast Cancer Incidence and Hormone Receptor Subtypes
Authors: Zeldin Jordan , Sandler Dale P. , Ogunsina Kemi , O'Brien Katie M.
Published: April 2024

Association between fibroids and hormone receptor status among only Non- Black / African American breast cancer cases
Supplementary Figure 2 from The Impact of Inherited Genetic Variation on DNA Methylation in Prostate Cancer and Benign Tissues of African American and European American Men
Authors: Delgado Dayana , Gillard Marc , Tong Lin , Demanelis Kathryn , Oliva Meritxell , Gleason Kevin J. , Chernoff Meytal , Chen Lin , Paner Gladell P. , Vander Griend Donald , Pierce Brandon L.
Published: April 2024

Supplementary Figure 2 shows the Principal Component Analysis (PCA) of SNP genotypes.
Supplementary Table 4 from Association of Fibroids, Endometriosis, and Gynecologic Surgeries with Breast Cancer Incidence and Hormone Receptor Subtypes
Authors: Zeldin Jordan , Sandler Dale P. , Ogunsina Kemi , O'Brien Katie M.
Published: April 2024

Association between fibroids and hormone receptor status among only Black / African American breast cancer cases
Supplementary Figure 10 from The Impact of Inherited Genetic Variation on DNA Methylation in Prostate Cancer and Benign Tissues of African American and European American Men
Authors: Delgado Dayana , Gillard Marc , Tong Lin , Demanelis Kathryn , Oliva Meritxell , Gleason Kevin J. , Chernoff Meytal , Chen Lin , Paner Gladell P. , Vander Griend Donald , Pierce Brandon L.
Published: April 2024

Supplementary Figure 10 shows the suggestive co-localization of PCa GWAS signal with a meQTL in the GGCX region.
Supplementary Figure 1 from The Impact of Inherited Genetic Variation on DNA Methylation in Prostate Cancer and Benign Tissues of African American and European American Men
Authors: Delgado Dayana , Gillard Marc , Tong Lin , Demanelis Kathryn , Oliva Meritxell , Gleason Kevin J. , Chernoff Meytal , Chen Lin , Paner Gladell P. , Vander Griend Donald , Pierce Brandon L.
Published: April 2024

Supplementary Figure 1 shows the principal components analysis (PCA) applied to DNAm data for all 300 samples differentiates tumor from normal tissue
Supplemental Figure 2 from Association of Fibroids, Endometriosis, and Gynecologic Surgeries with Breast Cancer Incidence and Hormone Receptor Subtypes
Authors: Zeldin Jordan , Sandler Dale P. , Ogunsina Kemi , O'Brien Katie M.
Published: April 2024

Results from logistic regression model among breast cancer cases assessing the relationship between history of fibroids or endometriosis and breast cancer subtype (ER+ versus ER-, PR+ versus PR-, HER2+ versus HER2- and triple-negative vs. non-triple-negative), stratified by race. The referent group is no fibroids (or no endometriosis), regardless of surgical history. Age adjusted, partially adjusted, and fully adjusted models are included.
Supplemental Figure 1 from Association of Fibroids, Endometriosis, and Gynecologic Surgeries with Breast Cancer Incidence and Hormone Receptor Subtypes
Authors: Zeldin Jordan , Sandler Dale P. , Ogunsina Kemi , O'Brien Katie M.
Published: April 2024

Histogram demonstrating the distribution of the age of diagnosis of both endometriosis and fibroids in the Sister Study cohort.
Data from Patterns of Cancer-Related Healthcare Access across Pennsylvania: Analysis of Novel Census Tract-Level Indicators of Persistent Poverty
Authors: Moss Jennifer L. , Geyer Nathaniel R. , Lengerich Eugene J.
Published: April 2024

AbstractBackground:
Persistent poverty census tracts have had ≥20% of the population living below the federal poverty line for 30+ years. We assessed the relationship between persistent poverty and cancer-related healthcare access across census tracts in Pennsylvania.
Methods:
We gathered publicly available census tract-level data on persistent poverty, rurality, and sociodemographic variables, as well as potential access to healthcare (i.e., prevalence of health insurance, last-year check-up), realized access to healthcare (i.e., prevalence of screening for cervical, breast, and colorectal cancers), and self-reported cancer diagnosis. We used multivariable spatial regression models to assess the relationships between persistent poverty and each healthcare access indicator.
Results:
Among Pennsylvania's census tracts, 2,789 (89.8%) were classified as non-persistent poverty, and 316 (10.2%) were classified as persistent poverty (113 did not have valid data on persistent poverty). Persistent poverty tracts had lower prevalence of health insurance [estimate = −1.70, standard error (SE) = 0.10], screening for cervical cancer (estimate = −4.00, SE = 0.17) and colorectal cancer (estimate = −3.13, SE = 0.20), and cancer diagnosis (estimate = −0.34, SE = 0.05), compared with non-persistent poverty tracts (all P < 0.001). However, persistent poverty tracts had higher prevalence of last-year check-up (estimate = 0.22, SE = 0.08) and screening for breast cancer (estimate = 0.56, SE = 0.15; both P < 0.01).
Conclusions:
Relationships between persistent poverty and cancer-related healthcare access outcomes differed in direction and magnitude. Health promotion interventions should leverage data at fine-grained geographic units (e.g., census tracts) to motivate focus on communities or outcomes.
Impact:
Future studies should extend these analyses to other states and outcomes to inform public health research and interventions to reduce geographic disparities.
Data from Rural–Urban Differences in Sun Exposure and Protection Behaviors in the United States
Authors: Dona Allison C. , Jewett Patricia I. , Henning-Smith Carrie , Ahmed Rehana L. , Wei Maria L. , Lazovich DeAnn , Vogel Rachel I.
Published: April 2024

AbstractBackground:
Evidence regarding whether rural residence is a risk factor for skin cancer is mixed. We compared sun exposure and protection behaviors between rural and urban residents by ethno-racial group in the United States.
Methods:
We analyzed data from three (2013–2018) National Health and Nutrition Examination Survey cycles. We compared self-reported sun exposure and protection measures (sunburn, time spent outside, sunscreen use, wearing long sleeves, staying in shade) by rural–urban residential status using survey-weighted logistic regression models stratified by ethno-racial group, adjusting for age, sex, income, education, body mass index, and smoking.
Results:
Hispanic rural versus urban residents more often reported sunburns in the past year [41.6% vs. 31.2%, adjusted OR (aOR): 1.46 (1.15–1.86)]. White rural versus urban residents more often spent 2+ hours outside on workdays [42.9% vs. 29.1%, aOR: 1.60 (1.27–2.01)] and non-workdays [72.2% vs. 64.8%, aOR: 1.45 (1.12–1.88)] and less often used sunscreen [26.0% vs. 35.1%, aOR: 0.74 (0.59–0.93)] and stayed in the shade [21.7% vs. 26.7%, aOR: 0.72 (0.57–0.89)]. Black rural versus urban residents stayed in the shade less often [31.6% vs. 43.9%, aOR: 0.60 (0.39–0.91)] but less often spent 2+ hours outside on non-workdays [47.6% vs. 56.8%, aOR: 0.67 (0.51–0.90)].
Conclusions:
Across all ethno-racial groups included, rural residents reported greater sun risk behaviors than urban residents, with some nuances by ethno-racial identity, suggesting rural residence is a potential risk factor for skin cancer.
Impact:
Sun protection promotion programs should consider rural–urban settings while also accounting for ethno-racial identities.
Figure S8 from Oral IRAK-4 Inhibitor CA-4948 Is Blood-Brain Barrier Penetrant and Has Single-Agent Activity against CNS Lymphoma and Melanoma Brain Metastases
Authors: Von Roemeling Christina A. , Doonan Bently P. , Klippel Kelena , Schultz Daniel , Hoang-Minh Lan , Trivedi Vrunda , Li Chenglong , Russell Rylynn A. , Kanumuri Raju S. , Sharma Abhisheak , Tun Han W. , Mitchell Duane A.
Published: April 2024

Supplemental Figure 8. (a) Representative IHC for Ki67 proliferative marker (pink pseudocolor) in B16F10 MBM tumors isolated on day 7 of treatment (day 12 of study) with vehicle control or CA-4948 (100 mg/kg). GFAP (astrocytes, green pseudocolor), CD45 (red pseudocolor), and DAPI nuclear stain (blue pseudocolor) included, scale bar = 100μm. (b) Quantitative comparison of Ki67 tissue expression shown in panel f between vehicle control (n=5) and CA-4948 (n=5), measured as the % of Ki67 positive cells within total cell population defined by DAPI nuclear count within the tumor area. P-value determined by unpaired t test.
Figure S6 from Oral IRAK-4 Inhibitor CA-4948 Is Blood-Brain Barrier Penetrant and Has Single-Agent Activity against CNS Lymphoma and Melanoma Brain Metastases
Authors: Von Roemeling Christina A. , Doonan Bently P. , Klippel Kelena , Schultz Daniel , Hoang-Minh Lan , Trivedi Vrunda , Li Chenglong , Russell Rylynn A. , Kanumuri Raju S. , Sharma Abhisheak , Tun Han W. , Mitchell Duane A.
Published: April 2024

Supplemental Figure 6. CA-4948 inhibition of MAPK and NF-κB signaling in MBM.
Supplementary Table 1 from Genomic Complexity Predicts Resistance to Endocrine Therapy and CDK4/6 Inhibition in Hormone Receptor–Positive (HR+)/HER2-Negative Metastatic Breast Cancer
Authors: Davis Andrew A. , Luo Jingqin , Zheng Tiantian , Dai Chao , Dong Xiaoxi , Tan Lu , Suresh Rama , Ademuyiwa Foluso O. , Rigden Caron , Rearden Timothy P. , Clifton Katherine , Weilbaecher Katherine , Frith Ashley , Tandra Pavan K. , Summa Tracy , Haas Brittney , Thomas Shana , Hernandez-Aya Leonel F. , Peterson Lindsay L. , Wang Xiaohong , Luo Shujun J. , Zhou Kemin , Du Pan , Jia Shidong , King Bonnie L. , Krishnamurthy Jairam , Ma Cynthia X.
Published: April 2024

PredicineATLAS gene panel.
Supplementary Figures S1-S15 from Genomic Complexity Predicts Resistance to Endocrine Therapy and CDK4/6 Inhibition in Hormone Receptor–Positive (HR+)/HER2-Negative Metastatic Breast Cancer
Authors: Davis Andrew A. , Luo Jingqin , Zheng Tiantian , Dai Chao , Dong Xiaoxi , Tan Lu , Suresh Rama , Ademuyiwa Foluso O. , Rigden Caron , Rearden Timothy P. , Clifton Katherine , Weilbaecher Katherine , Frith Ashley , Tandra Pavan K. , Summa Tracy , Haas Brittney , Thomas Shana , Hernandez-Aya Leonel F. , Peterson Lindsay L. , Wang Xiaohong , Luo Shujun J. , Zhou Kemin , Du Pan , Jia Shidong , King Bonnie L. , Krishnamurthy Jairam , Ma Cynthia X.
Published: April 2024

Supplementary Figure S1. High bTMB is associated with the presence of specific mutations.Supplementary Figure S2. ROC analysis to determine optimal bTMB cutoff.Supplementary Figure S3. High correlation between bTMB determined from WES and a 152-gene targeted sequencing panel.Supplementary Figure S4. Association between high cfDNA yield and shorter PFS.Supplementary Figure S5. High baseline tumor fraction is associated with shorter PFS.Supplementary Figure S6. bTMB scores are not associated with sites of metastatic spread.Supplementary Figure S7. Specific oncogenic signaling pathways are more frequently altered inpatients with high bTMB and bCNB scores.Supplementary Figure S8. Genomic landscape of all patients at baseline.Supplementary Figure S9. bTMB and bCNB at baseline vs. progression.Supplementary Figure S10. Correlation between baseline bCNB and bTMB.Supplementary Figure S11. Comparison of ctDNA dynamics as measured by ctDNA fraction andbCNB during treatment and progression.Supplementary Figure S12. Genome-wide plots of copy number changes across treatment timepoints.Supplementary Figure S13. Copy number changes detected for RB1 and BRCA2 genes acrosstreatment time points.Supplementary Figure S14. Relationship between ctDNA fraction and bTMB and bCNBSupplementary Figure S15. Relationship between tumor fraction and bCNB.
Figure S2 from Oral IRAK-4 Inhibitor CA-4948 Is Blood-Brain Barrier Penetrant and Has Single-Agent Activity against CNS Lymphoma and Melanoma Brain Metastases
Authors: Von Roemeling Christina A. , Doonan Bently P. , Klippel Kelena , Schultz Daniel , Hoang-Minh Lan , Trivedi Vrunda , Li Chenglong , Russell Rylynn A. , Kanumuri Raju S. , Sharma Abhisheak , Tun Han W. , Mitchell Duane A.
Published: April 2024

Supplemental Figure 2. CA-4948 affinity for murine IRAK-4.
Supplementary Figure S1 from Impact of Biomarker-Matched Therapies on Outcomes in Patients with Sarcoma Enrolled in Early-Phase Clinical Trials (SAMBA 101)
Authors: Carmagnani Pestana Roberto , Moyers Justin T. , Roszik Jason , Sen Shiraj , Hong David S. , Naing Aung , Herzog Cynthia E. , Fu Siqing , Piha-Paul Sarina A. , Rodon Jordi , Yap Timothy A. , Karp Daniel D. , Tsimberidou Apostolia M. , Pant Shubham , Zarzour Maria A. , Ratan Ravin , Ravi Vinod , Benjamin Robert S. , Lazar Alexander J. , Wang Wei-Lien , Daw Najat , Gill Jonathan B. , Harrison Douglas J. , Lewis Valerae O. , Roland Christina L. , Patel Shreyaskumar R. , Livingston J. Andrew , Somaiah Neeta , Ludwig Joseph A. , Conley Anthony P. , Hamerschlak Nelson , Gorlick Richard , Meric-Bernstam Funda , Subbiah Vivek
Published: April 2024

Treemap of most common drug mechanisms for patients treated in biomarker-matched studies.
Supplementary Table S2 from Randomized, Double-Blind, Placebo-Controlled Trial of MUC1 Peptide Vaccine for Prevention of Recurrent Colorectal Adenoma
Authors: Schoen Robert E. , Boardman Lisa A. , Cruz-Correa Marcia , Bansal Ajay , Kastenberg David , Hur Chin , Dzubinski Lynda , Kaufman Sharon F. , Rodriguez Luz M. , Richmond Ellen , Umar Asad , Szabo Eva , Salazar Andres , McKolanis John , Beatty Pamela , Pai Reetesh K. , Singhi Aatur D. , Jacqueline Camille M. , Bao Riyue , Diergaarde Brenda , McMurray Ryan P. , Strand Carrie , Foster Nathan R. , Zahrieh David M. , Limburg Paul J. , Finn Olivera J.
Published: April 2024

MDSC Values by Vaccine Immune Response vs. Non-Response
Supplementary Table S1 from Randomized, Double-Blind, Placebo-Controlled Trial of MUC1 Peptide Vaccine for Prevention of Recurrent Colorectal Adenoma
Authors: Schoen Robert E. , Boardman Lisa A. , Cruz-Correa Marcia , Bansal Ajay , Kastenberg David , Hur Chin , Dzubinski Lynda , Kaufman Sharon F. , Rodriguez Luz M. , Richmond Ellen , Umar Asad , Szabo Eva , Salazar Andres , McKolanis John , Beatty Pamela , Pai Reetesh K. , Singhi Aatur D. , Jacqueline Camille M. , Bao Riyue , Diergaarde Brenda , McMurray Ryan P. , Strand Carrie , Foster Nathan R. , Zahrieh David M. , Limburg Paul J. , Finn Olivera J.
Published: April 2024

Baseline advanced adenoma characteristics
Supplementary Figure S4 from BRD9 Degradation Disrupts Ribosome Biogenesis in Multiple Myeloma
Authors: Kurata Keiji , Samur Mehmet K. , Liow Priscilla , Wen Kenneth , Yamamoto Leona , Liu Jiye , Morelli Eugenio , Gulla Annamaria , Tai Yu-Tzu , Qi Jun , Hideshima Teru , Anderson Kenneth C.
Published: April 2024

BRD9 occupies promoter regions of target gene.
Supplementary Figure S2 from BRD9 Degradation Disrupts Ribosome Biogenesis in Multiple Myeloma
Authors: Kurata Keiji , Samur Mehmet K. , Liow Priscilla , Wen Kenneth , Yamamoto Leona , Liu Jiye , Morelli Eugenio , Gulla Annamaria , Tai Yu-Tzu , Qi Jun , Hideshima Teru , Anderson Kenneth C.
Published: April 2024

Ribosome biogenesis and translation signatures are upregulated in BRD9-depletion-sensitive MM cell lines.
Supplementary Figure S1 from BRD9 Degradation Disrupts Ribosome Biogenesis in Multiple Myeloma
Authors: Kurata Keiji , Samur Mehmet K. , Liow Priscilla , Wen Kenneth , Yamamoto Leona , Liu Jiye , Morelli Eugenio , Gulla Annamaria , Tai Yu-Tzu , Qi Jun , Hideshima Teru , Anderson Kenneth C.
Published: April 2024

Clinical impact and biological significance of BRD9 in multiple myeloma (MM) in vitro and in vivo.
Supplementary Data S2 from BRD9 Degradation Disrupts Ribosome Biogenesis in Multiple Myeloma
Authors: Kurata Keiji , Samur Mehmet K. , Liow Priscilla , Wen Kenneth , Yamamoto Leona , Liu Jiye , Morelli Eugenio , Gulla Annamaria , Tai Yu-Tzu , Qi Jun , Hideshima Teru , Anderson Kenneth C.
Published: April 2024

DifferentialExpression_RNAseq
Supplementary Tables S5-S11 from Integrating Tumor-Intrinsic and Immunologic Factors to Identify Immunogenic Breast Cancers from a Low-Risk Cohort: Results from the Randomized SweBCG91RT Trial
Authors: Stenmark Tullberg Axel , Sjöström Martin , Niméus Emma , Killander Fredrika , Chang S. Laura , Feng Felix Y. , Speers Corey W. , Pierce Lori J. , Kovács Anikó , Lundstedt Dan , Holmberg Erik , Karlsson Per
Published: April 2024

Supplementary MethodsTable S5. Clinical characteristics of the Sjöström and Servant cohortsTable S6. Comparison of included versus excluded patientsTable S7. 10-year follow-up for local recurrence (IBTR). Flexible parametric survival analysis with Royston-Parmar (RP) regression models used in Figures 2 and 3Table S8. 10-year follow-up for local recurrence (IBTR). Flexible parametric survival analysis with Royston-Parmar (RP) regression models with adjustment for other covariatesTable S9. Absolute number of events within different tertiles of Immunescore and Proliferative Index and depending on RT treatmentTable S10. Unadjusted and adjusted analysis of the interaction between the Integrated model and RT in the SweBCG91RT cohortTable S11. Distribution of subtypes in the tertiles of the Integrated score among high-risk patients
Supplementary Data S1 from BRD9 Degradation Disrupts Ribosome Biogenesis in Multiple Myeloma
Authors: Kurata Keiji , Samur Mehmet K. , Liow Priscilla , Wen Kenneth , Yamamoto Leona , Liu Jiye , Morelli Eugenio , Gulla Annamaria , Tai Yu-Tzu , Qi Jun , Hideshima Teru , Anderson Kenneth C.
Published: April 2024

Correlations of dBRD9-A susceptibility
Supplementary Tables S1-S4 from Integrating Tumor-Intrinsic and Immunologic Factors to Identify Immunogenic Breast Cancers from a Low-Risk Cohort: Results from the Randomized SweBCG91RT Trial
Authors: Stenmark Tullberg Axel , Sjöström Martin , Niméus Emma , Killander Fredrika , Chang S. Laura , Feng Felix Y. , Speers Corey W. , Pierce Lori J. , Kovács Anikó , Lundstedt Dan , Holmberg Erik , Karlsson Per
Published: April 2024

Supplementary Table S1 Demographics of the training cohortsSupplementary Table S2 Immunscore modelSupplementary Table S3 Proliferative Index ModelSupplementary Table S4 Immunescore:Proliferative Index
Supplementary Figure S4 from Integrating Tumor-Intrinsic and Immunologic Factors to Identify Immunogenic Breast Cancers from a Low-Risk Cohort: Results from the Randomized SweBCG91RT Trial
Authors: Stenmark Tullberg Axel , Sjöström Martin , Niméus Emma , Killander Fredrika , Chang S. Laura , Feng Felix Y. , Speers Corey W. , Pierce Lori J. , Kovács Anikó , Lundstedt Dan , Holmberg Erik , Karlsson Per
Published: April 2024

The interaction between the Integrated model and RT was significant in an unadjusted analysis (p=0.004) and an analysis adjusted for histological grade, age, ER status, and tumor size (p=0.008). The figure shows the predicted 10-year cumulative incidence of IBTR with 95% confidence intervals based on Integrated model score stratified by RT, based on Royston-Parmar models with estimates from Table S10. The stpm2 macro for Stata was used for the calculations. The dotted vertical lines represent percentiles of the Integrated score.
supplementary table 1 from Pilot Study of Recurrent Ewing's Sarcoma Management with Vigil/Temozolomide/Irinotecan and Assessment of Circulating Tumor (ct) DNA
Authors: Anderson Peter , Ghisoli Maurizio , Crompton Brian D. , Klega Kelly S. , Wexler Leonard H. , Slotkin Emily K. , Stanbery Laura , Manning Luisa , Wallraven Gladice , Manley Meghan , Horvath Staci , Bognar Ernest , Nemunaitis John
Published: April 2024

supplementary table
Supplementary Figure S1 from Integrating Tumor-Intrinsic and Immunologic Factors to Identify Immunogenic Breast Cancers from a Low-Risk Cohort: Results from the Randomized SweBCG91RT Trial
Authors: Stenmark Tullberg Axel , Sjöström Martin , Niméus Emma , Killander Fredrika , Chang S. Laura , Feng Felix Y. , Speers Corey W. , Pierce Lori J. , Kovács Anikó , Lundstedt Dan , Holmberg Erik , Karlsson Per
Published: April 2024

Gene sets from the molecular signatures database were used to create a model measuring immunological activity and immunomodulatory tumor-intrinsic factors. These were merged to create a model considering the interaction between the antitumoral immune response and tumor-intrinsic immunomodulatory factors.
Supplementary Figure S7 from NPY Methylated ctDNA is a Promising Biomarker for Treatment Response Monitoring in Metastatic Colorectal Cancer
Authors: Janssens Katleen , Vanhoutte Greetje , Lybaert Willem , Demey Wim , Decaestecker Jochen , Hendrickx Koen , Rezaei Kalantari Hassan , Zwaenepoel Karen , Pauwels Patrick , Fransen Erik , Op de Beeck Ken , Van Camp Guy , Rolfo Christian , Peeters Marc
Published: April 2024

Copy number alteration (CNA) profile of patient 24 based on shallow whole-genome sequencing (sWGS) of the baseline cfDNA sample.
Supplementary Figure S5 from NPY Methylated ctDNA is a Promising Biomarker for Treatment Response Monitoring in Metastatic Colorectal Cancer
Authors: Janssens Katleen , Vanhoutte Greetje , Lybaert Willem , Demey Wim , Decaestecker Jochen , Hendrickx Koen , Rezaei Kalantari Hassan , Zwaenepoel Karen , Pauwels Patrick , Fransen Erik , Op de Beeck Ken , Van Camp Guy , Rolfo Christian , Peeters Marc
Published: April 2024

Normalized methylation ratio.
Supplementary Table S2 from Zinc Finger MYND-Type Containing 8 (ZMYND8) Is Epigenetically Regulated in Mutant Isocitrate Dehydrogenase 1 (IDH1) Glioma to Promote Radioresistance
Authors: Carney Stephen V. , Banerjee Kaushik , Mujeeb Anzar , Zhu Brandon , Haase Santiago , Varela Maria L. , Kadiyala Padma , Tronrud Claire E. , Zhu Ziwen , Mukherji Devarshi , Gorla Preethi , Sun Yilun , Tagett Rebecca , Núñez Felipe J. , Luo Maowu , Luo Weibo , Ljungman Mats , Liu Yayuan , Xia Ziyun , Schwendeman Anna , Qin Tingting , Sartor Maureen A. , Costello Joseph F. , Cahill Daniel P. , Lowenstein Pedro R. , Castro Maria G.
Published: April 2024

Table S2. Liquid Chromatography and Mass Spectrometry Measurement of 2-hydroxyglutarate in the Conditioned Media of mIDH1 GCCs untreated, treated with vehicle (DMSO), or mIDH1 inhibitor (AGI-5198 or DS1001b)
Supplementary Table S1 from Zinc Finger MYND-Type Containing 8 (ZMYND8) Is Epigenetically Regulated in Mutant Isocitrate Dehydrogenase 1 (IDH1) Glioma to Promote Radioresistance
Authors: Carney Stephen V. , Banerjee Kaushik , Mujeeb Anzar , Zhu Brandon , Haase Santiago , Varela Maria L. , Kadiyala Padma , Tronrud Claire E. , Zhu Ziwen , Mukherji Devarshi , Gorla Preethi , Sun Yilun , Tagett Rebecca , Núñez Felipe J. , Luo Maowu , Luo Weibo , Ljungman Mats , Liu Yayuan , Xia Ziyun , Schwendeman Anna , Qin Tingting , Sartor Maureen A. , Costello Joseph F. , Cahill Daniel P. , Lowenstein Pedro R. , Castro Maria G.
Published: April 2024

Table S1. RNA sequencing comparison data
Supplementary Figure S1 from NPY Methylated ctDNA is a Promising Biomarker for Treatment Response Monitoring in Metastatic Colorectal Cancer
Authors: Janssens Katleen , Vanhoutte Greetje , Lybaert Willem , Demey Wim , Decaestecker Jochen , Hendrickx Koen , Rezaei Kalantari Hassan , Zwaenepoel Karen , Pauwels Patrick , Fransen Erik , Op de Beeck Ken , Van Camp Guy , Rolfo Christian , Peeters Marc
Published: April 2024

Consort diagram.
Supplementary Methods S1 from Zinc Finger MYND-Type Containing 8 (ZMYND8) Is Epigenetically Regulated in Mutant Isocitrate Dehydrogenase 1 (IDH1) Glioma to Promote Radioresistance
Authors: Carney Stephen V. , Banerjee Kaushik , Mujeeb Anzar , Zhu Brandon , Haase Santiago , Varela Maria L. , Kadiyala Padma , Tronrud Claire E. , Zhu Ziwen , Mukherji Devarshi , Gorla Preethi , Sun Yilun , Tagett Rebecca , Núñez Felipe J. , Luo Maowu , Luo Weibo , Ljungman Mats , Liu Yayuan , Xia Ziyun , Schwendeman Anna , Qin Tingting , Sartor Maureen A. , Costello Joseph F. , Cahill Daniel P. , Lowenstein Pedro R. , Castro Maria G.
Published: April 2024

Supplementary Methods
Supplementary Figure S2 from Influence of Genomic Landscape on Cancer Immunotherapy for Newly Diagnosed Ovarian Cancer: Biomarker Analyses from the IMagyn050 Randomized Clinical Trial
Authors: Landen Charles N. , Molinero Luciana , Hamidi Habib , Sehouli Jalid , Miller Austin , Moore Kathleen N. , Taskiran Cagatay , Bookman Michael , Lindemann Kristina , Anderson Charles , Berger Regina , Myers Tashanna , Beiner Mario , Reid Thomas , Van Nieuwenhuysen Els , Green Andrew , Okamoto Aikou , Aghajanian Carol , Thaker Premal H. , Blank Stephanie V. , Khor Victor K. , Chang Ching-Wei , Lin Yvonne G. , Pignata Sandro
Published: April 2024

Mutations in A, BRCA1 but not in B, BRCA2, are associated with PD-L1-positive tumors.
Data from NPY Methylated ctDNA is a Promising Biomarker for Treatment Response Monitoring in Metastatic Colorectal Cancer
Authors: Janssens Katleen , Vanhoutte Greetje , Lybaert Willem , Demey Wim , Decaestecker Jochen , Hendrickx Koen , Rezaei Kalantari Hassan , Zwaenepoel Karen , Pauwels Patrick , Fransen Erik , Op de Beeck Ken , Van Camp Guy , Rolfo Christian , Peeters Marc
Published: April 2024

AbstractPurpose:
Analysis of methylation markers in liquid biopsies is a promising technique for the follow-up of patients with metastatic colorectal cancer (mCRC), because they can be used in all patients, regardless of their mutational status. Therefore, we studied the value of NPY methylation analysis in circulating tumor DNA (ctDNA) for accurate response monitoring in patients with mCRC in the PANIB trial.
Experimental Design:
The PANIB trial was a randomized phase II trial designed to compare FOLFOX plus panitumumab and FOLFOX plus bevacizumab in patients with RAS wild-type unresectable mCRC. The results of sequential liquid biopsies were correlated with results of imaging.
Results:
Forty patients were included from six Belgian hospitals. Analysis of the liquid biopsies revealed that higher baseline levels of methylated ctDNA was associated with a significantly shorter overall survival [HR, 1.015; 95% confidence interval (CI), 1.005–1.025; P = 0.002]. Furthermore, 37 patients provided at least two liquid biopsies. Thirty-one of them showed a decrease in the methylation ratio after the start of therapy, which corresponded with stable disease or response on imaging at the first evaluation. When comparing the panitumumab and bevacizumab arm, significantly higher objective response and early tumor shrinkage rates were observed in the panitumumab arm (P = 0.048 and 0.015, respectively). However, due to a small study population, the trial was underpowered to detect a significant difference in survival.
Conclusions:
The results of this study confirm that baseline methylated ctDNA is a prognostic marker and indicate that NPY methylation is a promising marker for response monitoring in patients with mCRC.